MAGEA6 and melanoma: In analyzing the clinical trial results, ex vivo ELISPOT assays were performed to detect IFNγ-producing CD8 and CD4 T-cell responses specific to the DC vaccine loaded melanoma-associated antigens Tyrosinase, MART-1 and MAGE-A6.